Skip to main content
Premium Trial:

Request an Annual Quote

SQI Diagnostics, Isis Ink Immunogenicity Assay Development Deal

NEW YORK (GenomeWeb News) – Toronto-based life sciences and diagnostics company SQI Diagnostics today announced a method development deal with Isis Pharmaceuticals.

The deal covers the development of a multiplexed assay using SQI's Ig Plex multiplexing immunogenicity technology. Financial and other terms of the agreement were not disclosed.

SQI said that using its Ig Plex tests in clinical studies provides drug development firms quantitative results for multiple anti-drug antibody isotypes in one test. It also provides the use of SQI's automated systems to improve the benefits of multiplexing during a drug development's immunogenicity testing phase, and enables the drug developer to get ahead of emerging regulatory guidelines covering immunogenicity testing.

"We believe that our multiplexing solutions and services are highly complementary with Isis' extensive portfolio of drugs under development," SQI CEO Andrew Morris said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.